EP2205234A4 - METHOD AND COMPOUNDS FOR THE TREATMENT OF RETINOL-BASED DISEASES - Google Patents

METHOD AND COMPOUNDS FOR THE TREATMENT OF RETINOL-BASED DISEASES

Info

Publication number
EP2205234A4
EP2205234A4 EP08834564A EP08834564A EP2205234A4 EP 2205234 A4 EP2205234 A4 EP 2205234A4 EP 08834564 A EP08834564 A EP 08834564A EP 08834564 A EP08834564 A EP 08834564A EP 2205234 A4 EP2205234 A4 EP 2205234A4
Authority
EP
European Patent Office
Prior art keywords
retinol
compounds
treatment
methods
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08834564A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2205234A2 (en
Inventor
Nathan L Mata
Kim B Phan
Tam V Bui
Mustapha Haddach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revision Therapeutics Inc
Original Assignee
Revision Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revision Therapeutics Inc filed Critical Revision Therapeutics Inc
Publication of EP2205234A2 publication Critical patent/EP2205234A2/en
Publication of EP2205234A4 publication Critical patent/EP2205234A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP08834564A 2007-09-27 2008-09-16 METHOD AND COMPOUNDS FOR THE TREATMENT OF RETINOL-BASED DISEASES Withdrawn EP2205234A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97576507P 2007-09-27 2007-09-27
US98132207P 2007-10-19 2007-10-19
PCT/US2008/076499 WO2009042444A2 (en) 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases

Publications (2)

Publication Number Publication Date
EP2205234A2 EP2205234A2 (en) 2010-07-14
EP2205234A4 true EP2205234A4 (en) 2010-12-22

Family

ID=40512081

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08834564A Withdrawn EP2205234A4 (en) 2007-09-27 2008-09-16 METHOD AND COMPOUNDS FOR THE TREATMENT OF RETINOL-BASED DISEASES

Country Status (8)

Country Link
EP (1) EP2205234A4 (en:Method)
JP (1) JP2010540541A (en:Method)
KR (1) KR20100097098A (en:Method)
CN (1) CN101873852A (en:Method)
AU (1) AU2008305303A1 (en:Method)
CA (1) CA2699773A1 (en:Method)
IL (1) IL204728A0 (en:Method)
WO (1) WO2009042444A2 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN102459209A (zh) * 2009-04-16 2012-05-16 武田药品工业株式会社 用于预防或治疗糖尿病(等)的n-酰基-n’-苯基哌嗪的衍生物
WO2012071369A2 (en) * 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
EP2647713B1 (en) * 2010-12-02 2018-02-21 Daiichi Sankyo Company, Limited Modified single-strand polynucleotide
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2705247T3 (es) 2013-03-14 2019-03-22 Univ Columbia 4-fenilpiperidinas, su preparación y uso
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
BR112016025356B1 (pt) 2014-04-30 2023-04-18 The Trustees Of Columbia University In The City Of New York Compostos de 4-fenilpiperidinas substituídas, composições e seus usos
CN115197160A (zh) 2014-10-24 2022-10-18 武田药品工业株式会社 杂环化合物
JP6646586B2 (ja) * 2014-10-24 2020-02-14 武田薬品工業株式会社 複素環化合物
EP4142796A4 (en) * 2020-04-29 2024-06-26 Saliogen Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF HEREDITARY MACULAR DEGENERATION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526534A (en) * 1948-07-03 1950-10-17 Dow Chemical Co Di-(aryloxy)-methanes
US4255152A (en) * 1978-09-05 1981-03-10 Ciba-Geigy Corporation Process for the dyeing of hydrophobic fibres
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS577480A (en) * 1980-06-16 1982-01-14 Sankyo Co Ltd 4-alkoxy-6-phenoxymethyl-2-pyrone derivative
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526534A (en) * 1948-07-03 1950-10-17 Dow Chemical Co Di-(aryloxy)-methanes
US4255152A (en) * 1978-09-05 1981-03-10 Ciba-Geigy Corporation Process for the dyeing of hydrophobic fibres
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SANDHAM ET AL: "2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/J.BMCL.2007.05.019, vol. 17, no. 15, 1 August 2007 (2007-08-01), pages 4347 - 4350, XP022144702, ISSN: 0960-894X *
ULVEN TROND ET AL: "Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 23, November 2006 (2006-11-01), pages 6638 - 6641, XP002608837, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
IL204728A0 (en) 2010-11-30
JP2010540541A (ja) 2010-12-24
WO2009042444A3 (en) 2009-05-14
WO2009042444A2 (en) 2009-04-02
CA2699773A1 (en) 2009-04-02
AU2008305303A1 (en) 2009-04-02
KR20100097098A (ko) 2010-09-02
EP2205234A2 (en) 2010-07-14
CN101873852A (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
EP2205234A4 (en) METHOD AND COMPOUNDS FOR THE TREATMENT OF RETINOL-BASED DISEASES
EP2209371A4 (en) COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY
EP2118074A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIAC DISEASES
FR20C1061I2 (fr) Anticorps anti-cd38 pour le traitement du cancer
EP2352517A4 (en) METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES
EP2144612A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MITOCHONDRY FUNCTION
EP2273882A4 (en) BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
EP2091955A4 (en) ALKOXY COMPOUNDS FOR THE TREATMENT OF DISEASES
EP2376656A4 (en) METHOD AND DETERMINATION OF THE EFFECTIVENESS OF A GLUCOCORTICOID TREATMENT OF EOSINOPHILIAN ESOPHAGITIS
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
EP2262364A4 (en) OXADIAZOANTHRACEN COMPOUNDS FOR THE TREATMENT OF DIABETES
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP2004181A4 (en) ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR ASSOCIATED DISEASES
EP2328417A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING BETA-AMYLOID-MEDIATED DISEASES AND SYNNUCLEOPATHIES
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
EP2340242A4 (en) COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
EP2382201A4 (en) PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES
EP1983085A4 (en) DEVICE FOR TREATING FIBER OPERATORS
EP2349320A4 (en) COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
EP2010216A4 (en) MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
EP2365747A4 (en) METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
EP2068865A4 (en) METHOD AND COMPOSITIONS FOR THERAPY TREATMENT
EP2509596A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF EYE DISEASES
EP2340027A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100419

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REVISION THERAPEUTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20101119

17Q First examination report despatched

Effective date: 20110929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

DAX Request for extension of the european patent (deleted)
18D Application deemed to be withdrawn

Effective date: 20120210